2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2593

The Effect of Tofacitinib on Bone Mineral Density in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
Abstract Number: 956

The Effect of Treatment Adjustments Aimed at DAS Remission on Physical Functioning in Undifferentiated and Rheumatoid Arthritis Patients in Low Disease Activity
Abstract Number: 114

The Effect of Triage Assessments on Identifying Inflammatory Arthritis and Reducing Rheumatology Wait Times in Ontario
Abstract Number: 1523

The Effect Size of Fibromyalgia on PG-VAS in Rheumatoid Arthritis Patients. Adjustment Proposal in DAS28-ESR
Abstract Number: 2315

The Effectiveness of Social Media in Recruiting for Rare Rheumatic Diseases
Abstract Number: 2609

The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated up to 19 Months with Tofacitinib
Abstract Number: 3026

The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study
Abstract Number: 2590

The Efficacy of Additional Immunoadsorption on the Modulation of Disease Activity in Patients with Severe Rheumatoid Arthritis
Abstract Number: 452

The Efficacy of Motivational Counselling and SMS-Reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis: A Randomised Controlled Trial
Abstract Number: 1449

The Efficiency of the Regulation of Ca2+ Entry through Calcium Release-Activated Calcium Channel in the Treatment of Rheumatoid Arthritis
Abstract Number: 2183

The Electronic Osteoarthritis Knee and Hip Quality of Life (OAKHQOL) Questionnaire: A Useful and Valid Alternative to Measure Health-Related Quality of Life in Knee Osteoarthritis
Abstract Number: 1119

The Enhanced Expression of mRNA for Calgranulins, S100A8, S100A9 and S100A12, in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Abstract Number: 1439

The EP4 Receptor Antagonist CR6086 Is More Effective Than Classical NSAID and DMARD Treatment in a Murine Model of Arthritis and in Human RA Synovial Explants
Abstract Number: 1168

The Epidemiology of Individuals Not Fully Meeting Classification Criteria for Systemic Lupus Erythematosus (SLE): The Georgia Lupus Registry
Abstract Number: 1432

The EULAR Systemic Sclerosis Impact of Disease Score – a New Patient-Reported Outcome Measure for Patients with Systemic Sclerosis Under Development

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].